Project 171230
Occurrence and roles of the lipid mediators of inflammation during pulmonary Influenza virus infections
Occurrence and roles of the lipid mediators of inflammation during pulmonary Influenza virus infections
Project Information
| Study Type: | Trial Randomized_Controlled_Trial |
| Therapeutic Area: | Mental_Health |
| Research Theme: | Biomedical |
| Disease Area: | generalized anxiety disorder |
| Data Type: | Canadian |
Institution & Funding
| Principal Investigator(s): | Borgeat, Pierre; Flamand, Louis |
| Institution: | Université Laval |
| CIHR Institute: | Infection and Immunity |
| Program: | |
| Peer Review Committee: | Pharmaceutical Sciences |
| Competition Year: | 2008 |
| Term: | 4 yrs 0 mth |
Abstract Summary
This research program is aimed at understanding how the body reacts to infection by viruses such as the Influenza virus, which is the pathological agent of flu. The Influenza virus causes a severe infection of airways (pneumonia) and is reponsible for more than 20,000 deaths annually in the U.S.A only. We will investigate if the immune response to viral infection in the lungs triggers the formation of a group of natural substances called the "lipidic mediators of inflammation". In fact, it is believed that it is the inflammatory reaction induced by the infection that causes the disease (and death) rather than the viral multiplication itself. These studies will provide very important informations which could rapidly lead to improvement of the treatment (using already available drugs) of flu and other airway infections such as infections by the SARS coronavirus, as well as of pneumonia caused by bacteria and fungi.
Research Characteristics
This project includes the following research characteristics:
Study Justification
"This proposal outlines a double-blind, randomized, placebo-controlled trial to assess the effectiveness and safety of extended-release quetiapine fumarate (quetiapine XR) as monotherapy for generalized anxiety disorder (GAD)."
Novelty Statement
"The goal is to provide new information for clinicians about the risks and benefits of quetiapine XR, an important treatment option for patients with GAD."
Methodology Innovation
double-blind, randomized, placebo-controlled trial of extended-release quetiapine fumarate for generalized anxiety disorder, with a dose-response evaluation